NEW YORK (GenomeWeb News) — Agendia yesterday said it has given Argentine distributor Teva & Tutor exclusive rights to market Agendia's MammaPrint microarray in Argentina and Paraguay.
 
Agendia, based in the Netherlands, said that this South American expansion is part of a larger global sales effort, and said this is "an important step in opening more markets."
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.